This program utilizes GLP-1 agonists, medications that help patients lose weight by improving their metabolism, enhancing feelings of fullness, and increasing insulin sensitivity
Because of that, the NICE recommendations lean towards individualised care: tailoring the dose, frequency and delivery method, following people up at around three months, and reviewing sooner if symptoms are severe or if someone is pregnant or breastfeeding
Published cases overwhelmingly involve the highest available doses: 2.4 mg subcutaneous semaglutide weekly or 15 mg tirzepatide weekly
AOD-9604 specifically targets fat cells to release stored fat and prevent new fat accumulation, making it a more direct lipolytic agent
(2013) 98:E116372
How Genetics and Biomarkers Support Safer Dosing Decisions Individual predisposition to GLP-1 and GIP pathway sensitivity varies significantly